Sign up
Pharma Capital

SkinBioTherapeutics awarded first patent in Australia

The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease
picture of Melbourne
Patent is SkinBioTherapetics' first in Oz

SkinBioTherapeutics PLC (LON:SBTX) has been granted a first patent in Australia for Skinbiotix, its probiotic skin health platform.

The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease and runs until 15 March 2033, the company said in a statement on Friday.

READ: SkinBioTherapeutics technology gets double green light - next stop human studies

Catherine O'Neill, SkinBioTherapeutics’ chief executive, said: "The Australian skincare market is a key global market.

“The progression and successful grant of the first national patent to emerge from the company's Skinbiotix patent family underpins the commercial potential worldwide.

"This is a step forward in preparing for human trials, which are scheduled for 2018."

PhilW.jpg
Why Invest In SkinBioTherapeutics PLC? Read More Here

Register here to be notified of future SBTX Company articles
View full SBTX profile

SkinBioTherapeutics PLC Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.